Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Abiraterone resistance in prostate cancer cells

ABSTRACT: Abiraterone resistance in prostate cancer cells

PROVIDER: PRJNA909815 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Abiraterone resistance in prostate cancer cells

Project description:Castration resistant prostate cancer (CRPC) develops resistance to antiandrogens affecting Androgen Receptor (AR) signaling through a variety of mechanism. Because of this, the efficacy of androgen receptor targeted therapy remains limited for many patients with CRPC. We developed C42B-Abiraterone (Abi) and resistance cells to study changes in transcriptomic profile compared to parental cells.

2023-01-01 | GSE220467 | GEO

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

Project description:Super Enhancers (SEs) play a key role in castration-resistant prostate cancer (CRPC) drug resistance. By integrating ChIP-seq and RNA-seq analyses, we identified aberrantly activated super enhancers at the ELF3 and JUNB loci driving their transcriptional up-regulation in abiraterone-resistant prostate cancer cells. Mechanistically, ELF3/JUNB complex directly interacted and activated WNT11 to promote drug resistance and neuroendocrine transformation of prostate cancer cells. In vitro and in vivo experiments confirmed that targeting ELF3/JUNB significantly restored abiraterone sensitivity. This study reveals a critical role of the SE-driven ELF3/JUNB-WNT11 axis in CRPC resistance, providing a new potential therapeutic target to overcome abiraterone resistance.

2026-09-03 | GSE303076 | GEO

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

2026-09-03 | GSE303356 | GEO

Characterization of an abiraterone ultra-responsive phenotype in castration-resistant prostate cancer patient-derived xenografts

Project description:To identify the molecular signature associated with abiraterone acetate (AA) response and mechanisms underlying AA resistance in castration-resistant prostate cancer patient-derived xenografts (PDXs).

2016-12-22 | GSE85672 | GEO

RNA sequencing analysis of VCaP cells resistant to abiraterone

Project description:Here, we analyze gene expression of prostate cancer cell line VCaP (VCaP WT) and VCaP after long time treatment with abiraterone (VCaP AA) in order to investigate possible resistance mechanisms to second-generation antiandrogens.

2024-06-30 | GSE196523 | GEO

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

Project description:Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11

| PRJNA1293943 | ENA

Enzalutamide resistance in prostate cancer cells

Project description:Enzalutamide resistance in prostate cancer cells

| PRJNA633640 | ENA

Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients

Project description:Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20-40% of the patients. We aim to identify predictive biomarkers for AA-treatment response and understand the mechanisms related to treatment resistance. Experimental Design: We used the Infinium Human Methylation 450K BeadChip to monitor modification profiles of cell-free circulating DNA (cfDNA) in 108 plasma samples collected from 33 AA-treated patients. Results: Thirty cytosines showed significant modification differences (FDR q < 0.05) between the AA-sensitive and AA-resistant patients during the treatment, of which 21 cytosines were differentially modified prior to treatment. In addition, the AA-sensitive patients, but not AA-resistant patients, lost interindividual variation of cfDNA modification shortly after starting AA-treatment, but such variation returned to initial levels in the later phases of treatment. Conclusions: Our findings provide a list of potential biomarkers for prediction of AA-treatment response, highlight the prognostic value of using cytosine modification variance as biomarkers, and shed new insights into the mechanisms of prostate cancer relapse in AA-sensitive patients.

2018-03-20 | GSE108462 | GEO

Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide

Project description:We report RNA sequencing data on serial biopsies of prostate cancer VCaP xenografts as the tumors pass from androgen-sensitivity (Pre-Cx), to castration resistance (CRPC, castration resistant prostate cancer), onto resistance to dual therapy with abiraterone plus enzalutamide (AER). From comparison of these RNAseq data sets, we were able to determine differentially expressed genes between the AER/CRPC and Pre-Cx states that could mediate resistance to androgen deprivation therapies.

2018-12-26 | GSE109708 | GEO

Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

Project description:Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]

| PRJNA1294880 | ENA